|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
National Crisis Supercedes Coverage Debate
Efforts to craft a Medicare pharmacy benefit may be sidelined by repercussions from the September attack.
Advertisement
Articles in this issue
over 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
PBMs: Merck-Medco in the Hot Seatover 24 years ago
A Five-Year Forecast: Clear Seas Ahead?over 24 years ago
Weak Bones, Strong Marketover 24 years ago
Approvals: Novartis’ Silver Liningover 24 years ago
Pfizer and others Pitch Inover 24 years ago
Oncology: EMEA Approval Lagsover 24 years ago
Illegal Sales in Indiaover 24 years ago
Health Plan Premiums: Pharma Takes the Blameover 24 years ago
Little Elan Becomes a Big DealAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5